{
    "Clinical Trial ID": "NCT00553410",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A: Continuous Letrozole",
        "  Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)",
        "  Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously",
        "INTERVENTION 2: ",
        "  Arm B: Intermittent Letrozole",
        "  Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months",
        "  Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the following criteria:",
        "  Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy",
        "  Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease",
        "  Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes",
        "  Clinically disease-free",
        "  Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or a sequential combination of both",
        "  When calculating 4-6 years, neoadjuvant endocrine therapy should not be included",
        "  No evidence of recurrent disease or distant metastatic disease",
        "  No prior bilateral breast cancer",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Must be postmenopausal by any of the following criteria:",
        "  Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for > 3 months)",
        "  Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol, luteinizing hormone [LH], and follicle-stimulating hormone [FSH] in the postmenopausal range)",
        "  Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range)",
        "  Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above",
        "  Clinically adequate hepatic function",
        "  No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy",
        "  No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral in situ breast carcinoma",
        "  No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up",
        "  No psychiatric, addictive, or any other disorder that compromises compliance with protocol requirements",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  More than 12 months since prior and no other concurrent endocrine SERM/AI therapy",
        "  Any type of prior adjuvant therapy allowed including, but not limited to, any of the following:",
        "  Neoadjuvant chemotherapy",
        "  Neoadjuvant endocrine therapy",
        "  Adjuvant chemotherapy",
        "  Trastuzumab (Herceptin\u00ae)",
        "  Ovarian ablation",
        "  Gonadotropin releasing hormone analogues",
        "  Lapatinib ditosylate",
        "  No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of bone loss), or any other investigational agent"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival (DFS)",
        "  Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.",
        "  Time frame: 5-year estimates, reported at a median follow-up of 60 months",
        "Results 1: ",
        "  Arm/Group Title: Arm A: Continuous Letrozole",
        "  Arm/Group Description: Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)",
        "  Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously",
        "  Overall Number of Participants Analyzed: 2426",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of patients  87.5        (86 to 88.8)",
        "Results 2: ",
        "  Arm/Group Title: Arm B: Intermittent Letrozole",
        "  Arm/Group Description: Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months",
        "  Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months",
        "  Overall Number of Participants Analyzed: 2425",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of patients  85.8        (84.2 to 87.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1004/2411 (41.64%)",
        "  Hemoglobin 1/2411 (0.04%)",
        "  Cardiac Arrhythmia-Other (Specify) 2/2411 (0.08%)",
        "  Cardiac-ischemia/infarction 21/2411 (0.87%)",
        "  Conduction abnormality/Atrioventricular heart block - AV block-2nd degree Mobitz Type I (Wenckebach) 0/2411 (0.00%)",
        "  Conduction abnormality/Atrioventricular heart block - AV block-third degree (complete AV block) 2/2411 (0.08%)",
        "Adverse Events 2:",
        "  Total: 1052/2417 (43.53%)",
        "  Hemoglobin 1/2417 (0.04%)",
        "  Cardiac Arrhythmia-Other (Specify) 2/2417 (0.08%)",
        "  Cardiac-ischemia/infarction 22/2417 (0.91%)",
        "  Conduction abnormality/Atrioventricular heart block - AV block-2nd degree Mobitz Type I (Wenckebach) 2/2417 (0.08%)",
        "  Conduction abnormality/Atrioventricular heart block - AV block-third degree (complete AV block) 0/2417 (0.00%)"
    ]
}